Kedrion S.p.A.

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Kedrion S.p.A. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 3 currently recruiting 3 completed later-stage tilt upper quartile by trial count

Kedrion S.p.A.: 8 sponsored US clinical trials, 3 recruiting.

Kedrion S.p.A. sponsors 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 7 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Immunodeficiency Disease, with 1 trials.

Upper-quartile sponsor footprint

Kedrion S.p.A. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 3

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06752356
RECRUITING Phase 3

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

NCT06963216
RECRUITING Phase 3

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT07059000
ACTIVE NOT RECRUITING Phase 3

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979
COMPLETED Phase 3

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

NCT03961009
TERMINATED Phase 4

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

NCT01531803
COMPLETED Phase 2

Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients

NCT01554956
COMPLETED Phase 3

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 6
Phase 4 1

Therapeutic Areas

Primary Immunodeficiency Disease 1
Chronic Primary Immune Thrombocytopenia (ITP) 1
Acquired Factor X Deficiency 1
Chronic Inflammatory Demyelinating Polyneuropathy 1

Where Kedrion S.p.A. enrollment is open (later-stage tilt)

3 recruiting of 8 indexed (38% open); 3 completed (38%).

Phase mix: 7 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Primary Immunodeficiency Disease (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kedrion S.p.A.: open-pipeline peers nationwide

Peers matched on 8 registered trials and 38% open enrollment, not the therapeutic-area sidebar.

Kedrion S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8.088.1 0%10%20%30%40% Total trials Recruiting share Kedrion S.p.A.AB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)American Thrombosis and Hemostasis NetworkAskBioAthletic Greens InternationalBanner Health
Kedrion S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kedrion S.p.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 38% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kedrion S.p.A. page

8 registered trials is a research-attention snapshot, not an endorsement of Kedrion S.p.A. or any single study.

  • 3 of Kedrion S.p.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Primary Immunodeficiency Disease is the condition Kedrion S.p.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Immunodeficiency Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kedrion S.p.A. pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.